Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Interest Income

Income earned on cash, deposits, and investments held by the company.

Johnson & JohnsonNYSE: JNJ

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income remains negative

Q3 FY2026 interest income was $0, compared with $227M a year earlier. Trailing-twelve-month interest income was $685M. Over 3 fiscal years it compounded at +29.2% a year.

Context

  • Interest income amounted to 1.1% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $171.25M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$1.06B-20.7% YoY
LTMSep 2026
$685M-37.7% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-20.7%——
3-year CAGR+29.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
1.06B USD
Year-over-year change
-20.7%
4-year CAGR
+111.3%

Interest Income vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.7% is the 5th highest of 8, against a peer median of -33.8%.
  • Interest income amounts to 0.7% of revenue for JNJ, versus a peer median of 0.3%.
JNJ Competitors
Interest Income for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$685M USD-37.7%+29.2%0.7%
PFEPfizer Inc.LTM Jun 2026$532M USD-9.1%+33.9%0.8%
AZNAstraZeneca PLCLTM Sep 2026$342.11M USD+13.7%+64.4%0.6%
SNYSanofiLTM Jun 2026€274.69M EUR-50.8%+25.1%0.6%
MRKMerck & Co., Inc.LTM Jun 2026$200M USD-55.7%+29.8%0.3%
ABBVAbbVie Inc.LTM Sep 2026$198M USD-33.8%+12.7%0.3%
GILDGilead Sciences, Inc.LTM Jun 2026$183M USD-39.8%+48.8%0.6%
GSKGSK plcLTM Jun 2026£106M GBP+24.7%-4.5%0.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$101M USD——0.2%
NVSNovartis AGLTM Jun 2026$0 USD—-0.2%0.0%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding JNJ) —-33.8%+27.4%0.3%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.